Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18697250 | 0.81 | HTT (0.30) | — | |
| SCHEMBL20564554 | 0.77 | TP53 (0.36) | TP53 | |
| Fluoride SCHEMBL8463241 | 0.75 | TP53 (0.35) | TP53 | |
| SCHEMBL29224274 | 0.74 | TDP1 (0.30) | — | |
| SCHEMBL5175757 | 0.72 | — | — | |
| SCHEMBL3974163 | 0.71 | TP53 (0.32) | TP53 | |
| SCHEMBL30322880 | 0.71 | TP53 (0.32) | TP53 | |
| Fluoride SCHEMBL8466578 | 0.71 | TP53 (0.32) | TP53 | |
| SCHEMBL1532379 | 0.71 | — | — | |
| SCHEMBL10180025 | 0.71 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040082623-A1 | Fmoc-l-leucine and derivatives thereof as ppar-gamma agonists | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2004-04-29 | — | — | US | disclosed |
| WO-2002000611-A9 | FMOC-L-LEUCINE AND DERIVATIVES THEREOF AS PPAR-GAMMA AGONISTS | INST NAT SANTE RECH MED (FR) | 2004-04-15 | — | — | WO | disclosed |
| EP-1294681-A2 | FMOC-L-LEUCINE AND DERIVATIVES THEREOF AS PPAR- GAMMA AGONISTS | ADEREGEM (Association pour le Développement de la Recherche en Génétique Moléculaire (FR) | 2003-03-26 | — | — | EP | disclosed |
| EP-1253944-A2 | PHARMACEUTICAL COMPOSITION COMPRISING A COMBINATION OF METFORMIN AND ANOTHER ANTIDIABETIC AGENT | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-11-06 | — | — | EP | disclosed |
| EP-1121129-A4 | METHOD FOR TREATING DIABETES EMPLOYING AN aP2 INHIBITOR AND COMBINATION | BRISTOL MYERS SQUIBB CO (US) | 2002-10-16 | — | — | EP | disclosed |
| WO-2002000611-A2 | FMOC-L-LEUCINE AND DERIVATIVES THEREOF AS PPAR-GAMMA AGONISTS | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2002-01-03 | — | — | WO | disclosed |
| EP-1121129-A1 | METHOD FOR TREATING DIABETES EMPLOYING AN aP2 INHIBITOR AND COMBINATION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2001-08-08 | — | — | EP | disclosed |
| WO-2001032158-A2 | PHARMACEUTICAL COMPOSITION COMPRISING A COMBINATION OF METFORMIN AND ANOTHER ANTIDIABETIC AGENT | BRISTOL-MYERS SQUIBB COMPANY (US) | 2001-05-10 | — | — | WO | disclosed |
| WO-2000015229-A1 | METHOD FOR TREATING DIABETES EMPLOYING AN aP2 INHIBITOR AND COMBINATION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2000-03-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040082623-A1 | Fmoc-l-leucine and derivatives thereof as ppar-gamma agonists | PPARA, PPARG, PPARD | TP53 2074/4885TGFBR1 1772/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.